Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia.

Publication Date

2020

Journal Title

BMJ Case Rep

Abstract

Recent studies have shown that BRAF inhibitors, such as vemurafenib, are effective in inducing long periods of remission in relapsed hairy cell leukaemia. Acute pancreatitis is one of the rare complications that is reported with vemurafenib use. As severe pancreatitis can be life threatening, physicians should be vigilant of this side effect and promptly treat patients that develop clinical signs and symptoms while receiving vemurafenib. We present an interesting case of vemurafenib-induced pancreatitis that not only resolved but also did not recur after reintroduction of the drug at a reduced dose.

Volume Number

13

Issue Number

9

Pages

e236073

Document Type

Article

Status

Faculty, Northwell Resident

Facility

School of Medicine; Northwell Health

Primary Department

General Internal Medicine

PMID

32928833

DOI

10.1136/bcr-2020-236073

For the public and Northwell Health campuses

Share

COinS